Patients' voices heard: new study compares brain tumor treatments through their eyes
NCT ID NCT07547163
First seen Apr 29, 2026 · Last updated Apr 29, 2026
Summary
This study looks at how patients with a slow-growing brain tumor (IDH-mutant grade 2 glioma) feel during treatment. It compares two groups: those getting radiotherapy and those taking a drug called vorasidenib. A third group just gets regular check-ups. The goal is to understand quality of life, symptoms, and anxiety from the patient's point of view, using simple questionnaires.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for GLIOMA are added.
Genom att skicka in godkänner du våra Användarvillkor
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
Genom att skicka in godkänner du våra Användarvillkor
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
Fondazione IRCCS Istituto Neurologico Carlo Besta
RECRUITINGMilan, Italy
Contact Phone: •••-•••-•••• Email: •••••@•••••
Contact Phone: •••-•••-•••• Email: •••••@•••••
Conditions
Explore the condition pages connected to this study.